ment, and patient survival. There were 4584 patients included, and 24% had CrCl Ͻ60 ml/min. Each 10-ml/min decrement in CrCl was associated with an increase in mortality (hazard ratio, 1.14; P Ͻ 0.0001). CABG was associated with a survival benefit among patients with both normal renal function and patients with CKD compared with medical management. In patients with normal renal function, CABG was not associated with survival benefit over PCI. However, in patients with CKD, CABG was associated with improved survival. PCI was associated with a survival benefit compared with medical management among patients with normal, mildly, and moderately impaired renal function. Among patients with severe CKD, PCI was not associated with improved survival. CABG is associated with greater mortality reduction than PCI in severe CKD.
Coronary artery disease (CAD) is highly prevalent and strongly associated with adverse outcomes among patients with endstage renal disease (ESRD). In 2000, mortality for patients with ESRD was 19.5% at 1 yr, with approximately half of the deaths due to cardiac disease (1) . Additionally, mortality rises to almost 60% during the year after myocardial infarction (2) . In a series of consecutive, incident dialysis patients who underwent cardiac catheterization, more than 60% of patients had significant CAD (defined as a Ͼ75% narrowing of a major coronary artery), with an average of 3.3 lesions per patient (3) . Poor outcomes for patients with ESRD are no doubt affected by CAD that is already established and relatively advanced at the time dialysis is initiated (4) .
Coronary artery revascularization has inferior outcomes among patients with chronic kidney disease (CKD). Patients with ESRD who undergo percutaneous coronary artery intervention (PCI) have nearly double the rate of restenosis (5, 6) and have a greater mortality risk after coronary artery bypass grafting (CABG; OR, 3.1; 95% CI, 2.1 to 4.7) than patients with normal renal function (7) . Comparatively, patients with ESRD may also have a survival benefit from CABG compared with PCI (2,8 -10) . CKD is associated with adverse outcomes among CAD patients after CABG (11) . It is an important predictor of mortality among patients admitted to a coronary care unit (12) and is associated with increased rates of complications after PCI (13) . The level of CKD at which these risks begin to increase and the comparative benefits of PCI and CABG among patients with CKD not yet receiving renal replacement therapy has not clearly been defined.
This analysis tests the hypothesis that a gradient of survival probabilities exists among patients with CAD and CKD that is a function of the severity of renal insufficiency, and that the therapeutic benefits for revascularization procedures may differ among patients with declining renal function. This study was therefore undertaken to evaluate this hypothesis, to define the effect of varying degrees of CKD on survival, and to compare the survival of patients with normal renal function and varying degrees of CKD according to treatment strategy (medical, PCI, or CABG).
Materials and Methods

Description of Data Set
The Duke Databank for Cardiovascular Diseases, described in detail previously (14 -20) , contains information on patient-specific demographics, clinical history, physical examination, selected laboratory measures, and cardiac catheterization and coronary artery revascularization procedures gathered prospectively on patients undergoing cardiac catheterization at Duke University Medical Center. The Duke Databank for Cardiovascular Diseases has systematically collected information on the clinical experience of all patients undergoing cardiac catheterization since 1969 incorporating information for after-hospital follow-up. Patients are contacted 6 and 12 mo after their enrollment cardiac catheterization and annually thereafter to obtain information on follow-up, including survival status, medications, and rehospitalizations. The follow up in our study population is 97% complete.
All patients who underwent cardiac catheterization for the assessment of CAD at Duke University Medical Center between 1995 and 2000 with documented stenosis Ն75% of at least one major coronary artery and with serum creatinine values measured within 30 d before angiography were included in this analysis. Assignment to either PCI or CABG was made on the basis of initial revascularization procedure during the 30-d period after cardiac catheterization. For the purposes of this analysis, PCI refers to all patients who underwent percutaneous intervention, including balloon angioplasty with or without coronary stenting. The majority of the patients who underwent PCI in this analysis (91.5%) underwent coronary stent placement. Medical therapy refers to patients whose initial treatment strategy (within 30 d after catheterization) did not include either PCI or CABG. Patients who had a prior PCI or CABG, or patients with valvular heart disease, congenital heart disease, obstructive or restrictive cardiomyopathy, and hemodynamic instability or poorly visualized coronary anatomy on catheterization were excluded. Patients treated medically who died early (within 5 d after index cardiac catheterization) were also excluded to eliminate patients who did not have the opportunity to undergo PCI or CABG, reducing the bias that might be attributed to medical therapy as a result of early death. Patients were also excluded if it was apparent that cardiac catheterization took place primarily for pretransplantation assessment.
Descriptive Analysis
Demographic and clinical factors were compared among cohorts of patients stratified on renal function and treatment strategy (PCI, CABG, or medical management). Renal function was evaluated using creatinine clearance (CrCl) as a continuous measurement. CrCl was calculated using the formula derived by Cockcroft and Gault (21) . Patients who had undergone renal transplantation were excluded. For descriptive purposes, normal renal function was defined as CrCl Ն90 ml/min; mild renal insufficiency, 60 to 89 ml/min; moderate renal insufficiency, 30 to 59 ml/min, and severe renal insufficiency, 15 to 29 ml/min (22) . Patients with CrCl Ͻ15 ml/min and patients who were receiving dialysis were considered to have ESRD. Patients were stratified into five levels of renal function: normal, mild, moderate, and severe renal dysfunction; and ESRD. Patients undergoing dialysis were not included in the survival analysis because serum creatinine and calculated CrCl are not valid measures of renal function in this population.
Demographic and clinical factors, as well as CAD treatment strategy were compared among cohorts of patients described by categories of renal dysfunction. Categorical variables were compared between groups using the Pearson 2 tests, and continuous variables were compared using the nonparametric Kruskal-Wallis test.
Statistical Analyses
Patient survival time was calculated from the time of initial cardiac catheterization to the date of death or last contact. The unadjusted distribution of patient survival stratified by management strategy was estimated in all renal function cohorts using the Kaplan-Meier method. Groups with moderate and severe CKD were combined for graphical display because of the small sample size among the group with severe CKD.
Cox proportional-hazard regression was used to estimate the relationships between survival and selected clinical and demographic variables. Candidate variables for this analysis included CrCl; CAD treatment strategy; CAD severity; CAD symptom severity; duration of CAD; family history of CAD; comorbidities, including hypertension, diabetes mellitus, and congestive heart failure (CHF); severity of CHF symptoms; initial clinical examination findings, including carotid bruit and ventricular gallop; left ventricular ejection fraction; and previous myocardial infarction. The models incorporated a modified Charlson index to adjust for comorbid diseases (23), such as rheumatic diseases, hepatic impairment, cerebrovascular disease, peripheral vascular disease, tumor or cancer, chronic obstructive pulmonary disease, and AIDS. History of renal disease and diabetes mellitus with end-organ damage were not included in the comorbidity index so that their associations with survival could be modeled independently.
Continuous baseline clinical variables were tested for linearity in relation to the log hazard and were transformed where appropriate to meet this linearity assumption. Those variables with univariable model log likelihood 2 of 2.5 or greater, as well as those thought to be clinically relevant, were included in a stepwise multivariable selection process.
The presence of effect modification of CrCl on both treatment strategy and diabetes mellitus were examined in separate multivariable models to determine if the relationship between CrCl and survival differed by the presence of diabetes mellitus or if the association between treatment strategy and survival differed by level of renal dysfunction. Once the final model was developed, the proportionalhazard assumption was checked for violations. Additional assessment of goodness of fit of the model was evaluated graphically by plotting log(Ϫlog(Survival)) versus log(time) and time and determining whether the relationships were linear. The c index, or probability of concordance between predicted probability and response, was used to quantify the predictive ability of the Cox model. A value of c ϭ 0.5 indicates purely random predictions, whereas c ϭ 1.0 designates perfect concordance (24) . The final model, including significant interactions, was validated using a bootstrapping method, and the corrected concordance index was compared with the original model's c index. (25, 26) .
In addition to standard covariate adjustments, factors favoring treatment selection were identified using propensity score analysis. Propensity scores were developed from binary logistic regression models and were represented in Cox regression models by three variables consisting of the linear score or logit from each of the three logistic models (i.e., CABG versus PCI, CABG versus medical therapy, PCI versus medical therapy). This step in the analysis adjusts for likelihood that patients will receive a given therapy in an observational database when treatment is not randomly assigned. (27) (28) (29) . Finally, because of recent concerns about possible misclassification of renal function among patients with normal GFR using prediction equations (30) , the robustness of the final model was validated by repeating the final model but substituting serum creatinine for CrCl as a predictor variable.
Hazard ratio (HR) plots of CAD treatment strategy associated with mortality risk adjusted for all of the variables in the final survival model were categorized by levels of renal function. To determine the CrCl value above which no further improvement in mortality was seen ("threshold"), spline functions (31) were tested in Cox regression models. Analyses were performed using SAS version 8.2 (SAS Institute, Cary, NC). All P values reported are 2-sided, and all confidence intervals reported are 95% intervals.
Results
Population Characteristics
A total of 4584 patients were included in the analysis; 923 patients were excluded because they did not have a serum creatinine measurement available. Compared with those included in the analysis, patients without serum creatinine measurements were similar in age, gender, race, CAD severity, left ventricular ejection fraction, CAD treatment strategy, and prevalence of comorbidities, including hypertension, CHF, peripheral vascular disease, and previous myocardial infarction. They were likely to have diabetes mellitus (32.6% versus 28.5%, P ϭ 0.02).
Compared with patients with normal renal function, patients with CKD were in general older; more often black; more often female; and more likely to have comorbidities such as hypertension, diabetes mellitus, cerebrovascular disease, peripheral vascular disease, and CHF (Table 1) . Left ventricular ejection fraction was lower among patients with worsening CKD. The median ejection fraction among patients with normal renal function was 55.9%, compared with 50.0% among patients with severe renal dysfunction. A similar pattern was noted when cardiac function was assessed by means of the conventional clinical sign of an audible ventricular gallop as a surrogate. Patients with worsening CKD also had increasing clinical severity of CHF by New York Heart Association criteria, greater frequency of left main disease, and greater frequency of three-vessel or severe CAD than those with normal renal function.
Among patients with normal renal function, 47.6% underwent PCI as initial intervention after angiography, 27.4% were treated initially with CABG, and 25.0% were managed medically. With increasing severity of CKD, medical therapy was chosen with greater frequency, from 29.2% among patients with mild CKD to 51.4% among patients with severe CKD. Additionally, as renal function worsened, patients were less likely to undergo PCI, decreasing from 35.7% of patients with mild CKD to 15.9% of patients with severe CKD. In spite of more severe CAD, patients with severe CKD underwent CABG at a similar frequency (32.7%) compared with those with normal renal function. Among patients with ESRD, PCI and CABG were performed at a similar frequency to patients with severe CKD (14.5% and 28%, respectively). Adjusted logistic regression analyses evaluating factors that predicted treatment choice suggested that symptom severity, severity of CAD, older age, and ejection fraction were the most important factors that influenced treatment selection (data not shown).
Survival Analysis
Patient survival longer than 5 yr was greatest for patients with normal renal function and gradually worsened for patients with mild, moderate, and severe renal insufficiency (Figure 1 ). In the adjusted main-effects survival model, declining CrCl was a strong predictor of mortality ( Table 2 ). The increased mortality risk associated with decreased renal function was apparent up to a threshold CrCl of 85 ml/min, above which the association was attenuated. Consequently, for these analyses, CrCl was arbitrarily truncated at 85 ml/min. Among patients with a calculated CrCl Յ85 ml/min, a decline of 10 ml/min resulted in a 14% increase in mortality risk (HR, 1.14; 95% CI, 1.09 to 1.20; P Ͻ 0.0001). When these analyses were repeated with the evaluation of serum creatinine as a predictor variable instead of CrCl, increasing serum creatinine was found to be an important mortality predictor, and the remainder of the survival model was essentially unchanged.
Patients without serum creatinine measurements available were noted to have greater mortality than those with serum creatinine and missing serum creatinine greater mortality (HR, 2.37; 95% CI, 1.81 to 2.75; P Ͻ 0.0001). Other predictors of increasing mortality include medical management compared with CABG or PCI, left ventricular impairment characterized by ejection fraction, increasing age, increasing severity of CAD, the presence of valvular disease, the history and severity of CHF, a history of myocardial infarction, a history of diabetes mellitus, and an S3 ventricular gallop as revealed at physical examination. When propensity scores were added to quantify the likelihood a treatment intervention was chosen for a particular patient, the model did not achieve a significantly better fit to the data (data not shown).
The regression diagnostics that were undertaken for the Cox model revealed that the proportional-hazard assumption was not grossly violated and the fit of the hypothesized survival distribution was met because log Ϫ log(survival) versus log-(time) was linear. The bootstrapping process revealed that the Cox survival model has high predictive accuracy. There was minimal change in the corrected c index (c ϭ 0.7765) compared with the original (c ϭ 0.7815). Thus, the constructed model was validated by using nearly unbiased estimates of model performance.
The presence or absence of a clinical history of diabetes mellitus modified the effect of CrCl on survival (P ϭ 0.004 for this interaction). The association between CrCl and mortality was more pronounced among patients without diabetes mellitus. These patients experienced a 22% increase in risk with each 10-ml/min decrease in CrCl (HR, 1.22; 95% CI, 1.14 to 1.30; P Ͻ 0.001). Although a similar trend was present, among patients with diabetes mellitus, a decline in CrCl was not associated with an increased risk of mortality that reached conventional levels of statistical significance (HR, 1.08, 95% CI, 0.98 to 1.20; P ϭ 0.11).
Association between Treatment Strategy and Mortality
To illustrate the relationship between treatment strategy and CKD, CrCl was grouped into severity levels as in the descrip-tive analysis, and HRs (with 95% CI) characterizing relative treatment differences were reported. Treatment with PCI was independently associated with a beneficial effect on mortality when compared with medical management of CAD (HR, 0.65; 95% CI, 0.52 to 0.81; P ϭ 0.0001). The effect of renal function on mortality interacted significantly with treatment (PCI versus medical management) (P ϭ 0.04). PCI was associated with a survival benefit among patients with mild renal insufficiency ( Figure 2A ). As renal function declined further, PCI failed to offer a significant survival benefit over medical management among patients with severe renal insufficiency. Treatment with CABG was associated with a survival benefit when compared with medical management (HR, 0.42; 95% CI, 0.34 to 0.52; P ϭ 0.0001). The association between CABG and mortality was similar among patients across all levels of renal function (Figure 2B ) (P ϭ 0.64 for interaction between CrCl and CABG versus medical management).
Treatment with CABG compared with PCI was associated with a HR of mortality of 0.65 (95% CI, 0.5 to 0.9; P ϭ 0.002) among the entire cohort. When patients were stratified on renal function, CABG (compared with PCI) had a beneficial association with survival among patients with moderate and severe renal insufficiency not demonstrated among patients with normal renal function and mild renal insufficiency ( Figure 2C ). a CHF, congestive heart failure; NYHA, New York Heart Association; PCI, percutaneous coronary artery intervention; CABG, coronary artery bypass grafting.
b Defined as stenosis of the left main coronary artery of Ն75%. c Defined as either left main coronary artery stenosis Ն75% or significant stenoses in three coronary arteries. Continuous variables are presented as median (25th and 75th percentile). Categorical or dichotomous variables are presented as percentages.
Discussion
CKD is highly prevalent and an important mortality predictor among patients with CAD. In general, patients with worsening renal function have an increased frequency of comorbidities, more severe left ventricular dysfunction, and worse CAD. In spite of more severe cardiac disease, a greater proportion of patients with CKD are managed medically after their first cardiac catheterization. Irrespective of disease severity or choice of therapeutic strategy (PCI, CABG, or medical therapy), the presence of CKD was associated with an increased risk of mortality. Finally, the presence of CKD was associated with a differential treatment effect on survival when comparing PCI, CABG, and medical therapy. Although patients with more advanced CKD experienced a survival benefit from CABG compared with medical management, the benefit associated with PCI compared with medical management failed to remain significant as renal function declined to the most severe range. CABG was associated with improved survival compared with PCI in patients with advanced CKD.
These data are consistent with previous studies demonstrating an increased risk of in-hospital death for patients with renal dysfunction after acute myocardial infarction (32) , an increased risk of death at 5 yr among older patients with renal dysfunction not selected for the presence of cardiac disease (29) , and an increased risk of death over 8 yr among patients admitted to the Cardiac Intensive Care Unit (12) . These earlier studies are, however, limited by the fact that they do not control for the increased severity of cardiac disease among patients with worsening renal function (28) , nor do they describe renal dysfunction in terms of serum creatinine greater than and less than 1.5 mg/dl (29) . Although the latter analysis examines risk associated with renal dysfunction described by CrCl, conclusions from this study are affected by the unavailability of patient weights in the calculation of CrCl and the use of a clearance normalized to a 72-kg person. This current analysis clarifies these earlier findings, describing the increased risk of mortality risk associated with CKD as present at CrCl levels as high as 85 ml/min.
Patients with CKD undergoing PCI have a reduced revascularization success rate with more complications compared with patients with normal renal function (13, 33, 34) , and patients with ESRD have nearly twice the rate of restenosis (6, 35) . This is the first comparison of outcomes among patients with CKD who have undergone PCI, CABG, or medical management. These results demonstrate that compared with medical management, PCI is associated with better outcomes than medical management among patients with mild renal insufficiency, but that this beneficial association is attenuated among patients with more advanced CKD. Interestingly, compared with PCI, CABG is associated with greater benefit among patients with more advanced renal dysfunction. These findings are consistent with previous studies that demonstrated a differential treatment benefit from PCI and CABG among patients with ESRD (2, 8, 36) . In combination with these previous studies, the current findings may suggest that the differential comparative outcomes associated with these treatment strategies increases on a continuum as renal function declines rather than as a step function when a patient reaches ESRD. These observations will need to be confirmed by prospective data. Interestingly, the increase in mortality risk associated with CKD was not as marked among patients with diabetes mellitus. This mechanism for this is not clear and may be a result of diabetes mellitus being a surrogate for CKD-related morbidity not accounted for in the multivariable survival model. The differential risk associated with declining renal function among patients with and without diabetes mellitus has not previously been demonstrated. Further research to determine the mechanisms contributing to this difference will be essential.
The increase in mortality risk associated with missing serum creatinine suggests the possibility that a higher proportion of patients with missing creatinine data may have undergone angiography on a more emergent basis and could possibly have had a higher baseline risk.
Although this study describes the epidemiology and outcomes for patients with concurrent renal and cardiac disease, its conclusions should be interpreted in the setting of certain limitations. Indication bias may affect the results of any observational study in that the indication for treatment may affect the outcomes. To be enrolled onto this study, patients had to be referred for cardiac catheterization. If referral for catheterization is affected by the presence of CKD because of concerns such as the risk of acute renal failure due to contrast nephrotoxicity (37) (38) (39) (40) , the generalizability of these results to the entire population of patients with concurrent renal and cardiac disease may be affected. Furthermore, if the presence of CKD influences choice of revascularization strategy, it may introduce a bias that may also in turn affect outcomes. Although this bias may not be entirely obviated, it is minimized through the use of multivariable modeling to control for factors such as severity of CAD, left ventricular dysfunction, and the presence of comorbidities using a modified Charlson index. Other limitations include the single-center experience represented by these data. Although this may limit the generalizability of conclusions drawn from smaller data sets as a result of the practice patterns of a single health care provider or group of providers, the clinical team providing care for the patients in this data set is sufficiently large that the practice patterns are diverse and minimize its impact.
There are more than 6 million Americans living with CKD (41, 42) . Because of the striking prevalence and impact of cardiac disease on this population (1), the treatment of CAD represents a critical intervention to improve survival. Although this analysis confirms that patients with CKD have a higher mortality risk than patients with normal renal function, more importantly, it demonstrates that intervention through PCI or CABG is associated with a reduction in this risk and that PCI may be associated with less benefit than CABG in severe CKD. Future research should focus on the mechanism for the differential effects of coronary artery revascularization strategy based on renal function to allow health care providers to tailor their treatment strategies of the patient with both renal and cardiac disease.
